Two Investing Legends Join Forces for One Night ONLY…

and reveal the massive market events that will shape 2020 — and what they recommend you do NOW with your money.

Tue, December 10 at 7:00PM ET
 
 
 
 

24 Biotechnology Stocks to Buy Now

24 Biotechnology Stocks to Buy Now

24 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Galapagos NV Sponsored ADR (GLPG) boosts its rating from a C to a B this week. The company also gets A’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of GLPG stock.

AbbVie, Inc. (ABBV) is seeing ratings go up from a C last week to a B this week. AbbVie, Inc. a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. The company also gets A’s in operating margin growth and return on equity. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Sarepta Therapeutics, Inc. (SRPT) shows solid improvement this week. The company’s rating rises from a C to a B. Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the treatment of both rare and infectious diseases. For more information, get Portfolio Grader’s complete analysis of SRPT stock.

Seattle Genetics, Inc.’s (SGEN) ratings are looking better this week, moving up to a B from last week’s C. Seattle Genetics, Inc. is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Cepheid (CPHD) improves from a C to a B rating this week. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CPHD stock.

This week, Five Prime Therapeutics, Inc. (FPRX) pushes up from a B to a A rating. The company also gets A’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FPRX stock.

The rating of Tobira Therapeutics, Inc. (TBRA) moves up this week, rising from a D to a B. For more information, get Portfolio Grader’s complete analysis of TBRA stock.

This week, Blueprint Medicines Corp.’s (BPMC) ratings are up from a C last week to a B. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of BPMC stock.

This is a strong week for Genomic Health, Inc. (GHDX). The company’s rating climbs to B from the previous week’s C. Genomic Health, Inc. is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For more information, get Portfolio Grader’s complete analysis of GHDX stock.

Xencor, Inc. (XNCR) earns a A this week, jumping up from last week’s grade of B. The company also gets A’s in sales growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of XNCR stock.

Ascendis Pharma A/S Sponsored ADR (ASND) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of ASND stock.

Lexicon Pharmaceuticals, Inc. (LXRX) shows solid improvement this week. The company’s rating rises from a C to a B. Lexicon Pharmaceuticals, Inc. researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of LXRX stock.

This is a strong week for ARIAD Pharmaceuticals, Inc. (ARIA). The company’s rating climbs to A from the previous week’s B. ARIAD Pharmaceuticals, Inc. is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

Natera, Inc. (NTRA) is seeing ratings go up from a D last week to a B this week. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of NTRA stock.

Inovio Pharmaceuticals, Inc.’s (INO) ratings are looking better this week, moving up to a B from last week’s C. Inovio Pharmaceuticals, Inc. engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. For more information, get Portfolio Grader’s complete analysis of INO stock.

Cytokinetics, Incorporated (CYTK) gets a higher grade this week, advancing from a C last week to a B. Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of CYTK stock.

Aldeyra Therapeutics, Inc. (ALDX) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

The rating of Keryx Biopharmaceuticals, Inc. (KERX) moves up this week, rising from a C to a B. Keryx Biopharmaceuticals, Inc. focuses on developing and commercializing pharmaceuticals for the treatment of cancer and renal disease. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of KERX stock.

This week, Kindred Biosciences, Inc.’s (KIN) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of KIN stock.

This week, Organovo Holdings, Inc. (ONVO) pushes up from a C to a B rating. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ONVO stock.

Amarin Corporation Plc Sponsored ADR (AMRN) boosts its rating from a C to a B this week. Amarin Corporation Plc Sponsored ADR focuses on developing the treatment for cardiovascular disease in the field of lipid science. The company also gets A’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMRN stock.

PharmAthene, Inc. (PIP) earns a A this week, jumping up from last week’s grade of B. PharmAthene, Inc. develops biological and chemical defense products. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of PIP stock.

Athersys, Inc. (ATHX) improves from a B to a A rating this week. Athersys, Inc. is a biopharmaceutical company that engages in the discovery and development of therapeutic products in various disease areas in the United States. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of ATHX stock.

This week, NanoViricides, Inc.’s (NNVC) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of NNVC stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/24-biotechnology-stocks-to-buy-now/.

©2019 InvestorPlace Media, LLC